IL136668A0 - Restin and methods of use thereof - Google Patents

Restin and methods of use thereof

Info

Publication number
IL136668A0
IL136668A0 IL13666898A IL13666898A IL136668A0 IL 136668 A0 IL136668 A0 IL 136668A0 IL 13666898 A IL13666898 A IL 13666898A IL 13666898 A IL13666898 A IL 13666898A IL 136668 A0 IL136668 A0 IL 136668A0
Authority
IL
Israel
Prior art keywords
restin
methods
yeast expression
expression system
proteins
Prior art date
Application number
IL13666898A
Other languages
English (en)
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of IL136668A0 publication Critical patent/IL136668A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
IL13666898A 1997-12-08 1998-12-08 Restin and methods of use thereof IL136668A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6788897P 1997-12-08 1997-12-08
US8266398P 1998-04-22 1998-04-22
US10853698P 1998-11-16 1998-11-16
PCT/US1998/026058 WO1999029856A1 (en) 1997-12-08 1998-12-08 Restin and methods of use thereof

Publications (1)

Publication Number Publication Date
IL136668A0 true IL136668A0 (en) 2001-06-14

Family

ID=27371250

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13666798A IL136667A0 (en) 1997-12-08 1998-12-08 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
IL13666898A IL136668A0 (en) 1997-12-08 1998-12-08 Restin and methods of use thereof
IL13666598A IL136665A0 (en) 1997-12-08 1998-12-08 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13666798A IL136667A0 (en) 1997-12-08 1998-12-08 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL13666598A IL136665A0 (en) 1997-12-08 1998-12-08 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof

Country Status (10)

Country Link
EP (3) EP1037983A1 (xx)
JP (3) JP2001526031A (xx)
KR (3) KR20010015869A (xx)
CN (3) CN1322246A (xx)
AT (1) ATE319840T1 (xx)
AU (3) AU749904B2 (xx)
CA (3) CA2313251A1 (xx)
DE (1) DE69833794D1 (xx)
IL (3) IL136667A0 (xx)
WO (3) WO1999029878A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833794D1 (de) * 1997-12-08 2006-05-04 Beth Israel Hospital Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
US6852691B1 (en) 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO2000017240A1 (de) * 1998-09-21 2000-03-30 Haemopep Pharma Gmbh Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen
IT1312077B1 (it) * 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
ES2245656T3 (es) * 1999-12-30 2006-01-16 Aventis Pharma S.A. Utilizacion de un vector que comprende un acido nucleico que codifica un factor anti-angiogeno para el tratamiento de las neovascularizaciones de la cornea.
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
CA2368681A1 (en) * 2000-02-10 2001-08-16 Zymogenetics, Inc. Anti-angiogenic intestinal peptides, zdint5
CN1311228A (zh) * 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽——人精子特异蛋白em1,em6－48和编码这种多肽的多核苷酸
EP1666595A1 (en) 2000-10-26 2006-06-07 Beth Israel Deaconess Medical Center, Inc. GAB2 (P97) gene and methods of use thereof
KR100579660B1 (ko) * 2003-08-18 2006-05-15 정인식 제미니바이러스 발현시스템을 이용한 재조합 신생혈관생성억제 단백질의 제조방법
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
WO2005021756A1 (en) * 2003-08-29 2005-03-10 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
EP2270055A4 (en) 2008-04-04 2011-06-29 Procell Therapeutics Inc CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体
EP2628748A1 (en) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin chimeras and uses thereof
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
AU2016270428B2 (en) 2015-06-05 2020-11-26 Musc Foundation For Research Development Endostatin fragments and variants for use in treating fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
NZ307044A (en) * 1995-04-26 2002-03-01 Childrens Medical Center Angiostatin fragments with antiangiogenic activity
BR9611174A (pt) * 1995-10-23 1999-09-14 Childrens Medical Center Proteína de endostatina isolada, e composições terapêuticas antiangiogénicas formadas com a mesma.
AU9673998A (en) * 1997-10-01 1999-04-23 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
AU1598599A (en) * 1997-11-20 1999-06-15 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
DE69833794D1 (de) * 1997-12-08 2006-05-04 Beth Israel Hospital Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia

Also Published As

Publication number Publication date
EP1038011A2 (en) 2000-09-27
AU1806599A (en) 1999-06-28
EP1037983A1 (en) 2000-09-27
IL136665A0 (en) 2001-06-14
CN1322246A (zh) 2001-11-14
KR20010015867A (ko) 2001-02-26
AU749904B2 (en) 2002-07-04
AU1808899A (en) 1999-06-28
JP2001526040A (ja) 2001-12-18
CA2313251A1 (en) 1999-06-17
CN1284130A (zh) 2001-02-14
EP1038011B1 (en) 2006-03-08
KR20010015869A (ko) 2001-02-26
KR20010015868A (ko) 2001-02-26
WO1999029878A2 (en) 1999-06-17
EP1037985A1 (en) 2000-09-27
CA2313705A1 (en) 1999-06-17
WO1999029856A1 (en) 1999-06-17
WO1999029855A1 (en) 1999-06-17
AU1718099A (en) 1999-06-28
CN1284134A (zh) 2001-02-14
CA2312287A1 (en) 1999-06-17
JP2001526031A (ja) 2001-12-18
AU753889B2 (en) 2002-10-31
JP2002503449A (ja) 2002-02-05
IL136667A0 (en) 2001-06-14
AU742866B2 (en) 2002-01-17
WO1999029878A3 (en) 1999-09-16
DE69833794D1 (de) 2006-05-04
ATE319840T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
IL136668A0 (en) Restin and methods of use thereof
NO2013009I1 (no) Alipogen tiparvovec
NZ313625A (en) Process for stabilizing proteins in an acidic environment with a high-ester pectin
DE69534778D1 (en) Cathepsin-02-protease
WO1996022308A3 (en) Appetite suppression factor and related methods
DE69425433T2 (de) Getränke-stabilisierungssystem
DE69841437D1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
HK1036475A1 (en) Erythropoietin analog-human serum albumin fusion protein
EP0946755A4 (en) METHOD AND COMPOSITION FOR MANIPULATING POLYPEPTIDES
WO2004007532A3 (en) Beta-sheet forming peptides and material made thereof
WO2001086416A3 (en) Distributed applications in a portable thread environment
AU9574198A (en) Method of affinity cross-linking biologically active, immunogenic peptides to antibodies
AU6011794A (en) Process and system for, respectively, the utilization and provision of fuel gas
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU3425700A (en) Non-ribosomal peptide synthetases, method for producing same and the use thereof
HK1054763B (zh) 免疫毒素聚變蛋白質以及它們的表達方式
AR001732A1 (es) Celulasa alcalina novedosa y método para producirla
DE69534133D1 (de) Herstellung von nisin-varianten
CA2270408A1 (en) Monoclonal antibodies against the ypydvpdya epitope, process for producing the same and their use
WO1998041535A3 (en) Activation of peptides
AU6832094A (en) Expansins, proteins that catalyze plant cell wall expansion and weakening of paper fiber connections
NZ334744A (en) Method for determining expression of aberrant forms of APC protein
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
AU4871997A (en) Pancreatic lipases and/or recombinant colipases and derived polypeptides produced by plants, methods for obtaining them and use thereof
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies